SEOUL-SEMICONDUCTOR
6.7.2020 11:02:12 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs have been adopted for horticulture LED lighting by the lighting solution company Fiberli , located in Turkey, one of the largest agricultural exporters in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200706005073/en/
While it is well known that natural sunlight is one of the key factors in growth cycle of a plant, most growers cultivating a variety of crops under sunlight have experienced difficulties in regulating their growth cycles due to adverse seasonal conditions. Replacing sunlight with LED lighting that closely matches natural sunlight enables growers to control the growth cycles and development of all types of crops all year-round in greenhouses and indoor farms.
Seoul Semiconductor’s SunLike Series natural spectrum LEDs are the world’s first LEDs to produce light that closely matches the spectrum of natural sunlight. The SunLike Series LEDs adopted for horticulture LED lighting by Fiberli achieved a full spectrum of light wavelengths from 380nm to 740nm, similar to the spectral curve of natural sunlight, with a color temperature of 5000K optimized to daylight spectra and color properties of CRI97, CQS97, TM30=100. In co-operation with Fiberli, Seoul Semiconductor has delivered an optimal horticulture lighting solution that fulfills the requirements of the light source for effective cultivation of all varieties of crops and flowers.
Fiberli introduces their innovative horticulture lighting with SunLike with a demo installation of 1500 m2 .
“We are proud to launch the innovative horticulture LED lighting in co-operation with Seoul Semiconductor. Its SunLike Series natural spectrum LEDs are the first and only true sunlight LEDs that enable growers to ensure better yields and a consistently high quality of crops. We believe that market demand for horticultural LED lighting with SunLike LEDs will expand,” said Hakan Ozturk, director of Fiberli.
“The horticulture lighting market is growing fast, and our SunLike Series natural spectrum LEDs will offer the considerable benefits for customers to achieve optimal horticulture lighting solutions,” said Dr. Kim, CTO and vice president of Seoul Semiconductor. “We are pleased to expand this horticulture LED portfolio and will further diversify the customer base worldwide,” added Dr. Kim.
SunLike Series natural spectrum LEDs were co-developed through the combination of Seoul Semiconductor’s optical semiconductor technology and Toshiba Materials’ TRI-R technology, which defines its original concept as “the light closest to the sun for human well-being.” TRI-R technology enables the spectrum of natural sunlight to be reproduced by a white LED light source. TRI-R is a registered trademark of Toshiba Material Co., Ltd.
# # #
About Fiberli
Fiberli is a lighting solutions company located in Turkey. In cooperation with partners, it researches and develops lighting systems that reflect market demand and provide the best solutions for customers. Fiberli mainly delivers lighting for industrial and office spaces, greenhouses, indoor farms, parking and sports facilities. Based on a broad lighting portfolio, Fiberli offers differentiated service to customer from optimal guidance on the most suitable lighting solutions throughout the installation process. For more information, please visit https://fiberli.com.tr/EN
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 13,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200706005073/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom